Inovio Pharmaceuticals Inc (INO)

HEALTH CARE: PHARMACEUTICALS
SIC: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

6769 MESA RIDGE RD. SAN DIEGO, CA 92121

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. INOVIO's lead immunotherapy candidate, VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, cleared high-risk HPV-16 and/or HPV-18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 91% of anal cancer, and 69% of vulvar cancer. Also in development are programs targeting HPV-related cancers and a rare HPV-related disease, recurrent respiratory papillomatosis (RRP); non-HPV-related cancers glioblastoma multiforme (GBM) and prostate cancer; as well as infectious disease DNA vaccine development programs in coronaviruses associated with COVID-19 diseases and MERS, Lassa fever, Ebola, and HIV. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA)/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)/Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. INOVIO also is a proud recipient of 2020 Women on Boards 'W' designation recognizing companies with more than 20% women on their board of directors.

Data as of 2021-07-19 08:32:15 -0400
Market Cap1.73 Billion Shares Outstanding209.399 Million Avg 30-day Volume4.346 Million
P/E Ratio-9.1869 Dividend Yield EPS-1.08
Price/Sales267.95 Debt to Equity1.13 EBITDA-166.564 Million
Price to Book Value2.97 Forward PE Enterprise Value1.225 Billion
Total Cash518.604 Million Current Debt41.539 Million Gross Profit6.455 Million
BETA0.52153 52-week High/Low27.95 / 5.81 Next Earnings Date2021-08-09 Price to Cash FLow (P/CF) -35.7798
Data provided by IEX Cloud
View SEC Filings from INO instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 209 226 -7.52% 40 (2.35%) 48 (2.79%) -16.67%
13F shares: 73.438 Million 65.776 Million 11.65% 17.561 Million 13.306 Million 31.98%
% Ownership 35.255 38.8269 -9.2% 8.4305 7.8543 7.34%
New Positions: 35 58 -39.66% 7 14 -50.0%
Increased Positions 86 71 21.13% 18 17 5.88%
Closed Positions 47 38 23.68% 14 11 27.27%
Reduced Positions 52 54 -3.7% 10 12 -16.67%
Total Calls 4.228 Million 4.789 Million -11.7% 1.218 Million 979.029 Thousand 24.4%
Total Puts 4.797 Million 5.479 Million -12.44% 1.611 Million 1.199 Million 34.37%
PUT/CALL Ratio 1.13 1.14 -0.88% 1.32 1.22 8.2%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding INO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding INO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

92.6 Thousand total shares from 4 transactions

Exercise Derivative Conversion (M)

13.8 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KIES PETER CFO

  • Officer
155,288 2021-06-09 8

HUMEAU LAURENT CHIEF SCIENTIFIC OFFICER

  • Officer
78,904 2021-06-09 6

SHEA JACQUELINE ELIZABETH CHIEF OPERATING OFFICER

  • Officer
21,592 2021-06-09 6

BENITO SIMON X

  • Director
162,655 2021-05-13 5

WEINER DAVID B.

  • Director
1,761,627 2021-05-13 6

YARNO WENDY L

  • Director
82,153 2021-05-13 2

ZOTH LOTA S.

  • Director
90,819 2021-05-13 2

MILLER ANN CALBY

  • Director
70,261 2021-05-13 2

SHEPARD JAY

  • Director
57,974 2021-05-13 2

DANSEY ROGER D

  • Director
0 2021-05-13 2

KIM JONG JOSEPH CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
2,430,804 2021-03-11 6

CABRERA ANGEL

  • Director
75,602 2020-05-08 0

COLLINS MORTON

  • Director
365,230 2019-05-11 0

BAGARAZZI MARK CHIEF MEDICAL OFFICER

  • Officer
100,672 2019-03-05 0

DHILLON AVTAR S

  • Director
106,002 2018-12-06 0

MAHMOUD ADEL

  • Director
22,669 2018-05-11 0

BICKERSTAFF GEORGE

  • Director
4,090 2018-03-21 0

SARDESAI NIRANJAN CHIEF OPERATING OFFICER

  • Officer
123,486 2018-03-09 0

WYSENSKI NANCY

  • Director
5,000 2016-05-13 0

MARXE AUSTIN W & GREENHOUSE DAVID M

  • 10% Owner
No longer subject to file 2012-12-03 0

WELLS KEITH H

  • Director
0 2011-05-13 0

WILLIAMS DAVID J

  • Director
0 2010-06-16 0

RASSAS KEVIN SR. VP BUSINESS DEVELOPMENT

  • Officer
No longer subject to file 2009-11-16 0

DHILLON PUNIT VP, FINANCE & OPERATIONS

  • Officer
0 2009-09-30 0

FONS MICHAEL VP, CORPORATE DEVELOPMENT

  • Officer
0 2009-09-30 0

NG TEE KHIANG

  • Director
0 2009-09-30 0

WHITE CHERYL JO CHIEF MEDICAL OFFICER

  • Officer
0 2009-06-29 0

CHONG CHIN CHEONG

  • Director
0 2008-12-09 0

HEPPELL JAMES L

  • Director
0 2008-08-14 0

RIETIKER STEPHEN

  • Director
0 2008-05-02 0

RIEDER ROBERT WILLIAM

  • Director
0 2008-05-02 0

BANDALI RIAZ AMIRALI

  • Director
0 2008-05-02 0

ESMAIL TAZDIN

  • Director
0 2008-05-02 0

GAN BENG LEE

  • Director
823,045 2008-05-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

HUMEAU LAURENT - Officer CHIEF SCIENTIFIC OFFICER

2021-06-11 16:25:53 -0400 2021-06-09 S 10,318 $9.07 d 78,904 direct yes -3.1425 -3.0303 0.0 1 -4.7138 5

KIES PETER - Officer CFO

2021-06-11 16:24:37 -0400 2021-06-09 S 33,750 $10.01 d 130,788 direct yes -3.1425 -3.0303 0.0 1 -4.7138 5

SHEA JACQUELINE ELIZABETH - Officer CHIEF OPERATING OFFICER

2021-06-11 16:26:51 -0400 2021-06-09 S 38,535 $10.01 d 21,592 direct yes -3.1425 -3.0303 0.0 1 -4.7138 5

KIES PETER - Officer CFO

2021-06-11 16:24:37 -0400 2021-06-09 M 13,750 $2.16 a 164,538 direct -3.1425 -3.0303 0.0 1 -4.7138 5

KIES PETER - Officer CFO

2021-06-11 16:24:37 -0400 2021-06-09 M 13,750 d 20,000 direct

KIES PETER - Officer CFO

2021-06-04 16:08:38 -0400 2021-06-03 S 10,000 $8.03 d 150,788 direct yes 1.7773 5.5687 1.7773 18.8389 3 -6.7536 27

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
INOVIO PHARMACEUTICALS INC INO 2021-07-23 22:15:03 UTC -2.5097 2.5897 100000
INOVIO PHARMACEUTICALS INC INO 2021-07-23 21:45:03 UTC -2.497 2.577 100000
INOVIO PHARMACEUTICALS INC INO 2021-07-23 21:15:03 UTC -2.497 2.577 100000
INOVIO PHARMACEUTICALS INC INO 2021-07-23 20:45:03 UTC -2.5582 2.6382 100000
INOVIO PHARMACEUTICALS INC INO 2021-07-23 20:15:05 UTC -2.5582 2.6382 100000
INOVIO PHARMACEUTICALS INC INO 2021-07-23 19:45:03 UTC -2.5582 2.6382 100000
INOVIO PHARMACEUTICALS INC INO 2021-07-23 19:15:03 UTC -2.5582 2.6382 55000
INOVIO PHARMACEUTICALS INC INO 2021-07-23 18:45:03 UTC -2.6033 2.6833 100000
INOVIO PHARMACEUTICALS INC INO 2021-07-23 18:15:03 UTC -2.6033 2.6833 100000
INOVIO PHARMACEUTICALS INC INO 2021-07-23 17:45:03 UTC -2.6033 2.6833 100000
INOVIO PHARMACEUTICALS INC INO 2021-07-23 17:15:02 UTC -2.6033 2.6833 100000
INOVIO PHARMACEUTICALS INC INO 2021-07-23 16:45:02 UTC -2.7131 2.7931 100000
INOVIO PHARMACEUTICALS INC INO 2021-07-23 16:15:03 UTC -2.7131 2.7931 90000
INOVIO PHARMACEUTICALS INC INO 2021-07-23 15:45:02 UTC -2.7131 2.7931 250000
INOVIO PHARMACEUTICALS INC INO 2021-07-23 15:15:03 UTC -2.7131 2.7931 250000
INOVIO PHARMACEUTICALS INC INO 2021-07-23 14:45:03 UTC -2.5197 2.5997 200000
INOVIO PHARMACEUTICALS INC INO 2021-07-23 14:15:03 UTC -2.5197 2.5997 200000
INOVIO PHARMACEUTICALS INC INO 2021-07-23 13:45:03 UTC -2.5197 2.5997 200000
INOVIO PHARMACEUTICALS INC INO 2021-07-23 13:15:03 UTC -2.5197 2.5997 200000
INOVIO PHARMACEUTICALS INC INO 2021-07-23 12:45:03 UTC -2.5197 2.5997 200000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund INO -23200.0 shares, $-215296.0 2021-03-31 N-PORT
RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund INO -1153.0 shares, $-10699.84 2021-03-31 N-PORT
AQR Funds- AQR Diversified Arbitrage Fund INO -316146.0 shares, $-2933834.88 2021-03-31 N-PORT
RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund INO -3024.0 shares, $-20593.44 2021-04-30 N-PORT

Elevate your investments